Investors & Media
News

2019
  • 07 November 2019
    Selvita Q3 2019 results: accelerated growth, 45 percent increase in commercial revenues and strong long-term outlook
  • 21 October 2019
    Selvita to Exhibit at the 9th Drug Discovery Innovation Programme
  • 16 October 2019
    Selvita and Ryvu Therapeutics Announce Independent Trading
    on the Warsaw Stock Exchange
  • 01 October 2019
    Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
  • 20 September 2019
    Selvita and Sandoz chemists’ research published in Heterocycles
  • 19 September 2019
    Selvita announces shareholder approval of corporate split and new name of Ryvu Therapeutics for oncology development company
  • 09 September 2019
    Polish Financial Supervision Authority approves Selvita Cro prospectus, allowing corporate split into two separately listed companies to proceed
  • 05 June 2019
    Selvita to exhibit at the 20th annual Drug Discovery Summit 2019 Conference
  • 09 May 2019
    Selvita appoints Tom Coulter as Integrated Drug Discovery Director
  • 14 April 2019
    Selvita to exhibit at the 14th annual Drug Discovery Chemistry Conference
  • 28 March 2019
    Selvita to separate oncology therapeutics and contract research business units into two global companies
  • 27 March 2019
    Selvita introduces new technologies and expands the range of services through PLN 14M infrastructure investments in 2018
  • 26 March 2019
    Selvita to exhibit at the Elrig Research & Innovation 2019 Conference
  • 11 March 2019
    Selvita to exhibit at the 3rd annual Drug Discovery Chemistry Conference
  • 15 February 2019
    Selvita analytical laboratory GMP certifications will be automatically recognized by the FDA
2018
  • 13 September 2018
    Selvita presents and exhibits at the upcoming Medicinal Chemistry Summit: USA
  • 08 May 2018
    Selvita and Sandoz chemists published in Bioorganic & Medicinal Chemistry
2017
  • 18 November 2017
    Selvita promotes Edyta Jaworska to The Management Board to strengthen development in Integrated Drug Discovery services
  • 18 October 2017
    Selvita exhibits at the 35th Medicinal Chemistry Symposium in Japan
  • 05 October 2017
    Selvita presents at the 4th Drug Discovery USA Congress
  • 28 August 2017
    Selvita exhibits at Chemoutsourcing
  • 24 August 2017
    Selvita will exhibit at 19th RSC/SCI Medicinal Chemistry Symposium
  • 06 June 2017
    Selvita presents at 18th Drug Discovery Summit in Berlin
  • 10 May 2017
    Selvita opens new research site in Poznan
  • 08 March 2017
    Selvita and Sandoz researchers publish paper on Tapentadol synthesis
2016
  • 01 December 2016
    Selvita will be exhibiting at the 5th MassBio CRO/CMO symposium
  • 23 November 2016
    Selvita exhibits at 34th Medicinal Chemistry symposium in Japan
  • 03 October 2016
    Selvita presents at Drug Discovery Congress USA
  • 22 September 2016
    Selvita announces a ten-year laboratory infrastructure development plan
  • 17 August 2016
    Selvita exhibits at ChemOutsourcing 2016
  • 09 August 2016
    Selvita signs a significant collaboration with the University of California, San Francisco (UCSF)
  • 11 March 2016
    Selvita bridges Krakow and San Francisco
  • 04 February 2016
    Selvita opens new research site in Poznan
2015
  • 15 December 2015
    Selvita joins the European network of laboratories EU Netval
  • 24 September 2015
    Selvita launches new company – bioinformatics and personalized medicine focused Ardigen
  • 18 September 2015
    Selvita establishes its first operations in the U.S.
  • 05 May 2015
    Selvita establishes its UK subsidiary in Cambridge
  • 16 March 2015
    Selvita expands its proteomics services offer
  • 20 February 2015
    Selvita presents at the 3rd annual Biosimilars & Biobetters congress
2014
  • 26 August 2014
    Selvita exhibits at the CPHI Worldwide 2014
selvita_logo

Contacts